FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6, 2017 – The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab trials and ordered the discontinuation of the lenalidomide/ dexamethasone/ pembrolizumab arm of the KEYNOTE-023 trial. All 3 studies were evaluating the PD-1 inhibitor in patients with multiple myeloma. The agency “determined … (leggi tutto)